Trial 1B-18-4

A double-blind, placebo-controlled, randomized phase III study of Ipatasertib in combination with Paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor– positive, her2-negative breast cancer

Type: Treatment
Phase: Phase III
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Janice Lu, M.D.
Other Trial Staff: Lusine Raddatz, D.M., Margarita Carranza, D.M., Alix Cohen, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.